Market News & Trends
Recipharm Announces Acquisition of Vibalogics & Arranta Bio
Recipharm is continuing to build its service offerings in new biologic modalities through the acquisition of Vibalogics and Arranta Bio….
Quotient Sciences Completes Integration of Drug Substance Into Translational Pharmaceutics Platform
Quotient Sciences recently announced it has integrated drug substance into its flagship Translational Pharmaceutics® platform. The newly integrated service unites drug substance, drug product, and…
Gracell Doses First Patients in First-in-Human Clinical Trial of Dual-Targeting CAR-T Therapy
Gracell Biotechnologies Inc. recently announced it has dosed multiple patients in a clinical trial evaluating GC012F, the company's autologous CAR-T therapeutic candidate dual-targeting B cell…
Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial
Evelo Biosciences, Inc. recently announced the first patient has been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815 for the treatment of…
Zai Lab Announces Breakthrough Therapy Designation
Zai Lab Limited recently announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for investigational….
Pharmazz Inc. Announces Completion of Enrollment of Phase 3 Clinical Trial
Pharmazz, Inc. recently announced its Phase 3 clinical trial evaluating sovateltide as a treatment for acute ischemic stroke is now fully enrolled. Sovateltide is a…
Veru Announces the Presentation of Updated Data From Phase 1b/2 Sabizabulin Study in Men With Metastatic Castration Resistant Prostate Cancer
Veru Inc. recently announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin in 80 men with metastatic castration resistant prostate cancer…
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase 2 Portion of the OVATION 2 Study With GEN-1 in Advanced Ovarian Cancer
Celsion Corporation recently announced that following a pre-planned interim safety review of 81 as treated patients randomized in the Phase 1/2 OVATION 2 Study with….
AREV Life Sciences Advances Developments, New Appointments & Relationships
AREV Life Sciences Global Corp. recently announced its new corporate acquisitions and maturation of multiple product lines that are being matched with appointments and expanding…
Spero Therapeutics Announces Positive Topline Results From Phase 1 Bronchoalveolar Lavage Clinical Trial
Spero Therapeutics, Inc. recently announced topline findings from its Phase 1 bronchoalveolar lavage (BAL) clinical trial of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate.…
Hillstream BioPharma Receives Orphan Drug Designation for Uveal Melanoma Treatment
Hillstream BioPharma Inc. recently announced the FDA granted Orphan Drug Designation to HSB-1216 for Uveal Melanoma (UM). Hillstream continues to….
Adial Pharmaceuticals Announces Closing of $10 Million Financing
Adial Pharmaceuticals, Inc. recently announced the closing of its previously announced registered direct offering, whereby a single accredited institutional investor purchased approximately….
Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study
Skye Bioscience, Inc. recently announced it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100 ophthalmic nanoemulsion in support of the company’s….
Rhythm Pharmaceuticals Announces Positive Interim Data From Long-Term Extension Study
Rhythm Pharmaceuticals, Inc. recently announced positive interim data from its long-term extension study evaluating setmelanotide in patients with Bardet-Biedl Syndrome (BBS). Rhythm will review these…
Revive Therapeutics Receives FDA Orphan Drug Designation
Revive Therapeutics Ltd. recently announced the US FDA has granted Orphan Drug Designation (ODD) for Bucillamine for the prevention of ischemia–reperfusion injury (IRI) during liver…
Catalent Expands Temperature-Controlled Clinical Supply Capabilities in Shanghai, China
Catalent recently announced it plans to expand its Waigaoqiao Free Trade Zone (FTZ) facility in Shanghai, China, to increase capacity for temperature-controlled storage and distribution…
BioXcel Therapeutics Presents Positive Data From Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer
BioXcel Therapeutics, Inc. recently announced results from its ongoing Phase 2 trial of BXCL701, the company's investigational, oral innate immunity activator, in metastatic castration-resistant prostate…
Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children With Congenital Hyperinsulinism
Zealand Pharma A/S recently announced completion of patient enrollment in the second Phase 3-trial, 17103, of dasiglucagon for the treatment of Congenital hyperinsulinism (CHI) in….
Neurocentria Obtains FDA Approval to Conduct Pivotal Phase 2b/3 Clinical Trial for Testing Safety & Efficacy of Drug Candidate NRCT-101SR in Adults With ADHD
Neurocentria Inc. has recently received FDA approval to conduct a pivotal Phase 2b/3 human clinical trial to test the efficacy and safety of its leading…
OKYO Pharma Announces Successful Completion of Pre-IND Meeting With FDA on the Development of OK-101 to Treat Dry Eye Disease
OKYO Pharma Limited recently announced the successful completion of a pre-IND (Investigational New Drug) meeting with the US FDA regarding the development plans for OK-101…
